Skip to main content
. 2021 Jun 21;118(26):e2107424118. doi: 10.1073/pnas.2107424118

Fig. 6.

Fig. 6.

Proposed model. Siglec-7 and Siglec-9 can inhibit the endogenous antitumor immune response as well as the response to tumor-targeting and checkpoint-targeting antibodies. Blockade of Siglec-7 and Siglec-9 releases this inhibition and enhances antitumor immunity.